KA/EN
Register
Medicines reference
Search
Search
Product

Sedan

Favourites

Acepromazine · Bioveta a.s.

1 form: gel. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
35 mg/ml, Gel · Dog Dog Sedation · By mouth: 1–2 mg/kgPremedication · By mouth: 3 mg/kg - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სედანი 35მგ/მლ პერორალური გელი ცხენებისა და ძაღლებისთვის
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Sedan 35 mg/ml, Gel

acepromazine 35 mg/ml, oral gel for horses and dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
6.8/10
Situational / acceptable
vetman assessment

Sedan

35 mg/ml, acepromazine 35 mg/ml, oral gel for horses and dogs
Assessed clinical scopeDog · Label-concordant oral tranquilisation for mild/moderate sedation and anaesthetic premedication in appropriately selected dogs · By mouth
Care settingPlanned veterinary sedation or premedication with pre-use examination, accurate syringe-volume check, quiet low-stimulus setting and cardiorespiratory/temperature monitoring appropriate to depth and procedure
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A transparent, legally authorised oral acepromazine presentation that can work for selected dogs, but it is not analgesia or a modern all-purpose fear drug. Non-reversible cardiovascular/temperature effects, variable response and the 10 ml syringe precision ceiling make it a situational choice.

Regulatory and scientific credibility8.5/10

The exact product has a detailed current AEMPS SPC, a current multi-country EU/EEA authorisation record and current Georgian registration. Composition, dog indications, PK, dose tables, both syringe designs and extensive safety limits are transparent; independent exact-Sedan outcome and pharmacovigilance data remain limited.

Clinical efficacy7.0/10

Acepromazine is an established canine tranquiliser and premedicant; the exact label includes oral PK and a small randomised study supports clinically relevant oral sedation near 2 mg/kg. Evidence for this exact gel and 1–3 mg/kg spectrum is mostly regulatory, response varies materially, and it supplies negligible analgesia or reliable control of severe fear/aggression.

Safety and tolerability5.5/10

Correctly selected healthy dogs often tolerate acepromazine, but alpha-1 blockade can cause prolonged hypotension, tachycardia/arrhythmia, hypothermia, ataxia and non-reversible excessive sedation; paradoxical excitation/aggression is possible. ABCB1, small-device precision, major comorbidity exclusions and clinically important interactions narrow the safe population.

Clinical practicality6.0/10

Oral gel avoids injection and has predictable labelled onset, but it must reach the tongue root and be swallowed, is not reversible, and can last about four hours. The Georgian 10 ml syringe moves only in 0.5 ml steps, making dogs under 17.5 kg and reduced ABCB1 doses difficult to deliver accurately; monitoring and a quiet setting remain necessary.

Full-course cost-effectiveness-

Current Georgian full-course price and pack-waste data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Acepromazine is a non-reversible tranquiliser with negligible analgesia. Do not perform a painful procedure under Sedan alone; provide procedure-appropriate analgesia and anaesthesia.
  • Do not use in hypotension, shock or hypovolaemia, hypothermia, anaemia/coagulopathy, cardiac or pulmonary failure, epilepsy, neonates or dogs under 3 months, hypersensitivity or severe emotional excitation.
  • ABCB1-1Delta mutant dogs can have deeper and longer sedation: reduce the calculated dose by 25–50%. Confirm that the reduced volume is physically deliverable with this 10 ml syringe; do not round upward for convenience.
  • The 10 ml syringe delivers 0.5 ml steps. Dogs under 17.5 kg require explicit veterinarian benefit–risk and volume-accuracy assessment; the separately marketed 1 ml fine-step syringe must not be assumed to be present in this pack.
  • Acepromazine lowers sympathetic tone. Monitor blood pressure, heart rate/rhythm, respiration/oxygenation, temperature and recovery; excessive sedation has no specific antagonist and dose escalation mainly prolongs effects and adverse events.
  • Response is variable and sound/visual responses can remain. Severe fear or aggression can persist or become paradoxical excitation/aggression; use low-stress handling and do not mistake immobility for anxiolysis or safety.
  • Avoid organophosphate antiparasitics, procaine and adrenaline; avoid or carefully manage other blood-pressure-lowering drugs. CNS depressants, opioids and anaesthetics potentiate sedation/hypotension and must be dose-adjusted and monitored.
  • Oral antacids can reduce acepromazine absorption. Record their timing and do not redose early for an apparently weak response before the 15–25-minute onset window and patient factors have been reassessed.
  • Use the lowest effective dose in brachycephalic and large breeds and reduce in hepatic disease or debility. Stabilise dehydration and temperature before elective sedation; pregnancy/lactation safety is unestablished and requires benefit–risk assessment.
  • Place the measured gel at the root of the tongue, briefly raise the head and confirm swallowing. Keep the patient quiet with low sensory stimulation; secure the syringe after use, protect from freezing and discard three months after opening.
Assessment sources
  1. Sedan AEMPS SPC2026
  2. Sedan EU authorisation2026
  3. Tranquiline VMD control2026
  4. FDA oral acepromazine control2023
  5. Oral acepromazine dog RCT1998
  6. AAHA anaesthesia 20202020
  7. ABCB1 acepromazine dogs2016
  8. Acepromazine haemodynamics2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Acepromazine35 mg/ml
Formulation Type
Gel
Administration route
By mouth
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სედანი 35მგ/მლ პერორალური გელი ცხენებისა და ძაღლებისთვის
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ CZ/V/0174/001; ES 4099 ESP
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Dogs, PO once at the root of the tongue and confirm swallowing: 1 mg/kg mild sedation, 2 mg/kg moderate sedation, or 3 mg/kg anaesthetic premedication. Expected onset 15–25 minutes and average duration about 4 hours. The Georgian 10 ml syringe delivers 0.5 ml steps: below 17.5 kg or when a 25–50% ABCB1 dose reduction is required, prescribe only after confirming that the calculated volume can be delivered accurately. Higher-than-label dosing prolongs effects and toxicity without reliably deepening sedation.
Dog
WeightSedation · By mouthPremedication · By mouth
Any weight 1–2 mg/kg 3 mg/kg
  • Sedation · By mouth (once): Sedation: 1.0 mg/kg mild (0.5 ml per 17.5 kg), 2.0 mg/kg moderate (1.0 ml per 17.5 kg), at the root of the tongue. The 10 ml syringe gives 0.5 ml steps: dogs under 17.5 kg only after a benefit-risk assessment.
  • Premedication · By mouth (once): Anaesthetic premedication: 3.0 mg/kg (1.5 ml per 17.5 kg).
Source:
Sedan EU authorisation
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
SEDAN 35 mg/ml oral gel for horses and dogs - EU decentralised authorisation record
EU Veterinary Medicines Information / Union Product Database, 2026

Known Contraindications

  • Critical
    Do not use with hypovolaemia or dehydration.
    Sources: EU SPC
  • Critical
    Do not use with blood disorders or coagulopathy.
    Sources: EU SPC
  • Critical
    Do not use in anaemic animals.
    Sources: EU SPC
  • Critical
    Do not use with heart failure.
    Sources: EU SPC
  • Critical
    Do not use with lung failure.
    Sources: EU SPC
  • Critical
    Do not use in epileptic animals.
    Sources: EU SPC
  • Critical
    Do not use in neonates or dogs under 3 months.
    Sources: EU SPC
  • Critical
    Do not use if hypersensitive to acepromazine or excipients.
    Sources: EU SPC
  • Critical
    Do not use with hypotension or shock, in hypothermic animals or in a state of severe excitement. Organophosphates and procaine increase its toxicity.
    Sources: EU SPC
  • Warning
    MDR1 (ABCB1-1 delta) dogs: deeper, longer sedation; reduce the dose by 25-50%.
    Sources: EU SPC
  • Caution
    Liver disease or debility: use with caution at a reduced dose.
    Sources: EU SPC
  • Caution
    Safety in pregnancy not studied: benefit-risk only.
    Sources: EU SPC
  • Caution
    Safety in lactation not studied: benefit-risk only.
    Sources: EU SPC

Known Drug Interactions

  • Major warning Acepromazine + Metoclopramide
    Concomitant use with phenothiazine neuroleptics such as acepromazine or with butyrophenones increases the risk of extrapyramidal effects: agitation, ataxia, tremor, abnormal movements, vocalization, and aggression. Both agents block D2 receptors, producing an additive effect.
    Recommendation: Avoid the combination where possible. If necessary, use the lowest metoclopramide dose and monitor the animal. Effects are transient and resolve after treatment stops; there is no specific antidote, and a quiet environment is recommended.
  • Minor warning Buprenorphine + Acepromazine
    Centrally acting drugs, including tranquillisers, sedatives, and hypnotics, can increase buprenorphine-induced drowsiness. Combined use with sedatives can also increase depression of heart rate and respiration.
    Recommendation: Reduce the sedative dose during premedication; monitor heart rate and respiration.
  • Minor warning Dexmedetomidine + Acepromazine
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Methadone + Acepromazine
    Methadone can potentiate analgesics, central nervous system depressants, and drugs that cause respiratory depression. Lower doses may be needed when these medicines are combined.
    Recommendation: Reduce doses when used in combination; monitor heart rate and respiration.
    Sources: Comfortan SPC

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (4 more) Hide additional products

Same therapeutic group 4

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗